



THE Clinical Pharmacy CONGRESS

POSTER ZONE 2016

Session C: Saturday Morning

Contents

Poster 1	3
Application of educational theory and online response system during placement induction sessions for pharmacy undergraduates	3
Poster 2	4
Medicines Optimisation: Successful introduction of biosimilar infliximab North Bristol NHS Trust..	4
Poster 3	6
COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY OF TYPE 2 DIABETES MELLITUS IN UKRAINE	6
Poster 4	7
An audit following up medical patients four weeks post discharge to establish if the changes made to their medications during their hospital admission were implemented in the community	7
Poster 5	9
Simulation – friend or foe? An investigation into student perceptions of clinical simulation as a teaching method for pharmacy undergraduate education.	9
Poster 6	11
Formulation of a pharmacy support staff development strategy, facilitating workforce planning and development opportunities within an Acute Teaching Trust	11
Poster 7	13
Using lean methodology to improve parenteral chemotherapy and monoclonal antibodies documentation processes.....	13
Poster 8	14
Cost comparison of oral capecitabine versus intravenous 5-fluorouracil/folinic acid in cancer based treatment.....	14
Poster 9	15

Poster 3

COST-EFFECTIVENESS ANALYSIS OF COMBINED THERAPY OF TYPE 2 DIABETES MELLITUS IN UKRAINE

Germanyuk T.A., doctor of medicine, professor of pharmacy department,
Ivko T.I., assistant of pharmacy department,
National Pirogov Memorial Medical University, Vinnytsya, Ukraine

Topicality. Type 2 diabetes mellitus (T2DM) gets the status non-infectious epidemic. T2DM needs effective and economically justified therapy in the limited financing of healthcare.

The purpose: scientific justification for the choice of schemes of combined therapy of type 2 diabetes mellitus. The object of the study: 1) retrospective analysis of 1792 inpatient's medical histories of the patients with T2DM; these patients were treated at the endocrinology clinics of Podolsky region of Ukraine in 2011-2013; 2) frequency analysis; 3) ATC/DDD-methodology; 4) cost-effectiveness analysis; 5) sensitivity analysis.

Results of research. Frequency analysis showed that the combined therapy with metformin + sulfonylurea was used in 66% of cases: metformin + glimepiride – in 45% of cases, metformin + gliclazide – in 14.5%, metformin + glibenclamide – in 6.1%. ATC/DDD-methodology showed that the cost for DDD of combination metformin + glimepiride was in the range from 2.70 to 8.88 UAH, metformin + gliclazide – 3.29-9.43 UAH, metformin + glibenclamide – 1.98-6.20 UAH. Cost-effectiveness analysis showed that the cost of unit of effectiveness for metformin + glibenclamide was in the range from 40.33 to 126.27 UAH, metformin + glimepiride – from 53.68 to 176.51 UAH, metformin + gliclazide – from 55.69 to 159.63 UAH, in the context of minimal and maximal prices of generics. The sensitivity analysis showed that the scheme of metformin + glibenclamide keeps pharmacoeconomic advantages to increased cost of DDD up to 17% in comparison with scheme metformin + gliclazide and to 15% in comparison with scheme metformin + glimepirid.

Conclusions. 1) Frequency analysis found that a combined therapy was used in 66% of cases; 2) ATC/DDD-methodology showed that the cost of DDD of investigated combined therapy was in the range from 1.98 to 9.43 UAH, in the context of minimal and maximal costs of generics of oral hypoglycemic drugs; 3) Cost-effectiveness analysis showed that the cost of unit of effectiveness for metformin + glibenclamide was in the range from 40.33 to 126.27 UAH, metformin + glimepiride – from 53.68 to 176.51 UAH, metformin + gliclazide – from 55.69 to 159.63 UAH; 4) The sensitivity analysis showed the stability of the results of the pharmacoeconomic study.